Thrombogenic and atherogenic activities of lysophosphatidic acid
- 17 June 2004
- journal article
- review article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 92 (6), 1086-1094
- https://doi.org/10.1002/jcb.20108
Abstract
Lysophosphatidic acid (LPA) has been identified as a biologically active lipid in mildly‐oxidized LDL, human atherosclerotic lesions, and the supernatant of activated platelets. The evidence that LPA has thrombogenic and atherogenic activities has increased substantially in recent years. Supporting the thrombogenic activity of LPA, analysis of the core region of human carotid plaques revealed recently the presence of alkyl‐ and acyl‐molecular species from LPA with high platelet‐activating potency (16:0 alkyl‐LPA, 20:4 acyl‐LPA). LPA, lipid extracts of atherosclerotic plaques, and the lipid‐rich core elicited shape change and, in synergy with other platelet stimuli, aggregation of isolated platelets. This effect was completely abrogated by prior incubation of platelets with LPA receptor antagonists. Furthermore, LPA at concentrations approaching those found in vivo, induced platelet shape change, aggregation, and platelet‐monocyte aggregate formation in blood. LPA‐stimulated platelet aggregation was mediated by the ADP‐stimulated activation of the P2Y1 and P2Y12 receptors. Supporting its atherogenic activity, LPA is a mitogen and motogen to vascular smooth muscle cells (VSMCs) and an activator of endothelial cells and macrophages. Recently, LPA has been identified as an agonist of the peroxisome proliferator activating receptor γ (PPARγ), which is a key regulator of atherogenesis. LPA elicits progressive neointima formation, which is fully abolished by GW9662, an antagonist of PPARγ. We propose that LPA plays a central role in eliciting vascular remodeling and atherogenesis. Furthermore, upon rupture of lipid‐rich atherosclerotic plaques, LPA may trigger platelet aggregation and intra‐arterial thrombus formation. Antagonists of LPA receptors might be useful in preventing LPA‐elicited thrombus formation and neointima formation in patients with cardiovascular diseases.Keywords
This publication has 41 references indexed in Scilit:
- Identification of p2y9/GPR23 as a Novel G Protein-coupled Receptor for Lysophosphatidic Acid, Structurally Distant from the Edg FamilyPublished by Elsevier BV ,2003
- Leptin Induces Endothelial Cell Migration Through Akt, Which Is Inhibited by PPARγ-LigandsHypertension, 2002
- A Critical Role of Platelet Adhesion in the Initiation of Atherosclerotic Lesion FormationThe Journal of Experimental Medicine, 2002
- PPAR activators inhibit endothelial cell migration by targeting AktBiochemical and Biophysical Research Communications, 2002
- Peroxisome Proliferator–Activated Receptor-γ Ligands Inhibit Nuclear but Not Cytosolic Extracellular Signal–Regulated Kinase/Mitogen–Activated Protein Kinase–Regulated Steps in Vascular Smooth Muscle Cell MigrationJournal of Cardiovascular Pharmacology, 2001
- Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA speciesFEBS Letters, 2000
- Mildly Oxidized LDL Induces Platelet Aggregation Through Activation of Phospholipase A 2Arteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombinBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1989
- Human platelet aggregation induced by 1-alkyl-lysophosphatidic acid and its analogs: A new group of phospholipid mediators?Biochemical and Biophysical Research Communications, 1982
- Lysophosphatidic acid-induced aggregation of human and feline platelets: Structure-activity relationshipBiochemical and Biophysical Research Communications, 1981